Xolair

Lea en español

Xolair
Xolair (the trade name for Omalizumab), is a drug that has been approved to treat teenagers and adults with severe allergic asthma since its introduction in Australia in 2002. Approved by the U.S. Food and Drug Administration (FDA) in 2014, it has been held out as being particularly effective for people who cannot be treated with H1 antihistamines or do not benefit from high doses of corticosteroids. It has also been used to treat people who suffer chronically from hives.

A number of adverse side effects have been linked to the use of Xolair, including:

  • Anaphylactic shock or anaphylaxis (a life-threatening allergic reaction)
  • Increased risk of heart disease
  • Increased risk of stroke
  • Masking of warning signs of certain cancers

If you or someone you love has suffered injury after being prescribed Xolair, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Defective Drugs & Medical Devices Topics

Latest Articles

Happy New Year 2020

Wishing you happy holidays and a wonderful new year. Best wishes from everyone at GetLegal.

23 Dec 2019, Monday

Slip-and-fall Claims on Commercial Property

Your Best Chance of Recovery When You Are Hurt on Business Premises As a general rule, all property…

02 Dec 2019, Monday

Thanksgiving—A Time of Gratitude

Life is about connection… about the power of relationships to help us find and nurture our best se…

27 Nov 2019, Wednesday